Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone
Overview
- Phase
- Not Applicable
- Intervention
- Current Domperidone
- Conditions
- Arrhythmias, Cardiac
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Enrollment
- 1608
- Primary Endpoint
- The occurrence of serious ventricular arrhythmia and sudden cardiac death (combined end point)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this retrospective observational study is to obtain information to confirm or contradict the results of prior studies on domperidone and sudden cardiac death. The population studied are the Saskatchewan residents who used domperidone or another type of medication known as a Proton Pump Inhibitor (PPI) between 1990 and 2005. Information will be collected from various sources including the Saskatchewan Health (SH) database and Cancer Registry.
Detailed Description
The purpose of this population-based, observational study is to evaluate the combined risk of serious ventricular arrhythmia (irregular heart rhythm) and sudden cardiac death in users of domperidone (a medication used to treat certain gastrointestinal disorders) compared with users of proton pump inhibitors (another group of medications used to reduce gastric or stomach acid production. The study will be conducted using patient information from Saskatchewan Health (SH) who had recorded dispensings of domperidone or a PPI from 1990 through 2005. The first objective of the study is to estimate the combined relative risk of the occurrence of a particular type of irregular heart rhythm known as serious ventricular arrhythmia (SVA) and sudden cardiac death SCD (defined as a natural death from an unexpected circulatory arrest) during current use of domperidone or current use of proton pump inhibitors (PPIs) as compared with nonuse in a diabetic population. The second objective is to estimate the combined relative risk of SVA and SCD during current use of domperidone or current use of PPIs as compared with nonuse in a non-diabetic population. Study drug dosing information not required for Observational Study
Investigators
Eligibility Criteria
Inclusion Criteria
- •Saskachewan residents who received domperidone or a proton pump inhibitor (PPI) between January 1, 1990, and December 31, 2005
Exclusion Criteria
- •Cancer free \>=1 year of history in the database before receiving the first dose of domperidone or a PPI
Arms & Interventions
001
Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
Intervention: Current Domperidone
002
Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
Intervention: Current proton pump inhibitor (PPI)
003
No Intervention Neither current domperidone nor current PPI
Intervention: No Intervention
Outcomes
Primary Outcomes
The occurrence of serious ventricular arrhythmia and sudden cardiac death (combined end point)
Time Frame: Retrospective study
Secondary Outcomes
- The second objective is to estimate the combined relative risk of SVA and SCD during current use of domperidone or current use of PPIs as compared with nonuse in a non-diabetic population.(Retrospective)